solid tumor
Conditions
Interventions
None listed
Sponsors
National cancer center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients participating, planning to participate in the prospective study to evaluate the feasibility of a comprehensive genomic profile test at the initial treatment in patients with solid tumors and its usefulness for treatment selection. Blood samples can be collected at either or both points prior to the first treatment or at the time of the progression disease. Patients who are already on second-line treatment will not be allowed to be enrolled. Patients with inadequate specimens (including insufficient specimen volume) or cases of failure for analysis by NGS testing. *Patients with lung cancer may be enrolled in the study with a specimen failure (insufficient specimen volume) or cases of failure for analysis to perform the Oncomain Dx Target Test multi-CDx system. Written consent for this study was obtained from the patients themselves.
Exclusion criteria
Exclusion criteria: -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify the rate of gene profiling successfully by liquid biopsy in patients with failure or no detection of tumor tissue based comprehensive genome profiling. | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify the rate of targetable gene alterations detected by liquid biopsy in patients with failure or no detection of tumor tissue based comprehensive genome profiling To compare the results of gene alterations by liquid biopsy with those by companion diagnostics (CDx) To identify the rate of MSI high detected by liquid biopsy in patients with failure or no detection of tumor tissue based comprehensive genome profiling To identify the rate of patients treated with targeted therapy based on the results of liquid biopsy | — |
Countries
Japan
Contacts
Public ContactTatsuya Yoshida
National cancer center hospital Department of Experimental Therapeutics
Outcome results
None listed